PlentyParanoid has some interesting math but we are several years away from $1B/year in revenues from drug sales to patients. Fortunately we should expect good movement from catalysts in the shorter term.

I'm keeping my focus on a near-term Brilacidin partnership which should push our market cap back up to $300M+. With good Prurisol or Kevetrin results and money in the bank we will likely press on toward a $500M-$750M market cap by the end of 2018. I've been bitten several times before when I predicted a substantially higher share price. This time feels different though...very excited about things to come.

A health to IPIX!